SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-122067
Filing Date
2022-11-25
Accepted
2022-11-25 14:00:10
Documents
5
Period of Report
2023-01-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2230379-2_def14a.htm DEF 14A 243386
2 GRAPHIC lg_vyne-4c.jpg GRAPHIC 28421
3 GRAPHIC sg_daviddomzalskinew01-bw.jpg GRAPHIC 7330
4 GRAPHIC tm2230379d2-px_01pagebw.jpg GRAPHIC 507508
5 GRAPHIC tm2230379d2-px_02pagebw.jpg GRAPHIC 200933
  Complete submission text file 0001104659-22-122067.txt   1269691
Mailing Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 221419698
SIC: 2834 Pharmaceutical Preparations